Clinical trial
Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients…
NCT00048724 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00048724 |
|---|---|
| Title | Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) |
| Official title | PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C, Cirrhosis |
| Intervention type | Biological |
| Interventions | peginterferon alfa-2b (SCH 54031) |
| Enrollment | 631 |
| Start date | Jun 1, 2002 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Nov 8, 2002 |
| Last update posted | Apr 4, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: